Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus REVATIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus REVATIO.
ADCIRCA vs REVATIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
REVATIO (sildenafil) is a phosphodiesterase type 5 (PDE5) inhibitor. By inhibiting PDE5, it increases cyclic guanosine monophosphate (cGMP) levels in pulmonary vascular smooth muscle, leading to vasodilation and reduced pulmonary vascular resistance.
10 mg orally three times daily.
20 mg orally three times daily, administered 4-6 hours apart.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life ~4 hours (range 3-5 hours) in steady state; similar in pulmonary arterial hypertension patients.
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Primarily hepatic metabolism (CYP3A4) to N-desmethyl sildenafil (active). Renal excretion accounts for ~80% as metabolites; ~13% fecal.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor